Preclinical Imaging Market Size to Reach USD 7.24 Billion by 2035 as Pharmaceutical R&D and Drug Discovery Investments Accelerate

The global preclinical imaging market is projected to grow from USD 4.58 billion in 2025 to USD 7.24 billion by 2035, driven by a surge in pharmaceutical research and development investments. This growth reflects the industry's increasing reliance on advanced imaging technologies to optimize drug discovery processes and enhance decision-making during the early stages of development. As pharmaceutical and biotechnology companies seek to mitigate rising costs and improve candidate selection, the adoption of high-end imaging solutions has become a critical component of modern drug pipelines.

According to a report by SNS Insider, the preclinical imaging sector is expanding at a compound annual growth rate (CAGR) of 4.69% as organizations like pharmaceutical firms and contract research organizations work to accelerate disease studies. The market's expansion is primarily fueled by the need to visualize biological activities and disease progression in real-time, allowing researchers to gain a deeper understanding of drug efficacy before clinical trials. In the United States, the market is expected to grow from USD 1.12 billion in 2025 to USD 1.85 billion by 2035, while Europe is forecasted to reach USD 1.95 billion in the same timeframe.

Within the technology landscape, optical imaging held the largest market share in 2025 at 11.9% due to its cost-effectiveness and sensitivity in molecular imaging. However, the multimodal and hybrid imaging segment—which includes integrated systems like PET/CT, PET/MRI, and SPECT/CT—is anticipated to experience the fastest growth as it provides a more comprehensive view of anatomical and functional status. From an application standpoint, research and development currently generates the most revenue, though drug discovery and development are poised for significant growth as imaging becomes essential for dosage optimization and biomarker discovery.

Pharmaceutical and biotechnology companies represent the largest end-user segment, accounting for 35.9% of the market in 2025, driven by heavy spending on pipeline expansion and the demand for research efficiency. Academic centers and research institutes are also expected to see high growth rates, supported by government grants for studies in oncology, neuroscience, and translational medicine. Regionally, North America remains the dominant force, capturing 28.3% of global revenue in 2025, bolstered by a robust healthcare research infrastructure and the early adoption of innovative imaging technologies.